Fabrinet Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Fabrinet on August 16, 2012. The filing primarily addresses corporate governance changes, including the appointment of a new director and the approval of executive and director compensation plans. It also references the issuance of a press release on August 20, 2012, regarding financial results for the fiscal quarter and year ended June 29, 2012.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the period ended June 29, 2012. These details are contained in the referenced press release (Exhibit 99.1) which is incorporated by reference but not included in the text of this 8-K.
Material Changes and Corporate Actions
- Director Appointment: Dr. Homa Bahrami was appointed as a Class I director and member of the Nominating and Corporate Governance Committee, effective August 16, 2012.
- Executive Incentive Plan: The Compensation Committee approved the Fiscal 2013 Executive Incentive Plan. Bonuses are based 100% on achieving revenue and non-GAAP EPS targets.
- Director Compensation: The Board approved increases to cash retainers for non-employee directors and updated equity grant structures.
Guidance, Outlook, and Performance Targets
The Fiscal 2013 Executive Incentive Plan establishes specific performance thresholds for executive bonuses:
- Revenue Target: Exceed $689 million for fiscal 2013.
- Non-GAAP EPS Target: Exceed $1.54 per share for fiscal 2013.
- Bonus Structure: Target bonuses require exceeding both metrics by 10%. Maximum bonuses (up to 200% of base salary for some) require exceeding metrics by 20% or more. Aggregate target bonus payout is approximately $1.4 million, with a maximum of approximately $2.8 million.
Important Facts for Investor Verification
- Verify the actual financial results for the quarter and year ended June 29, 2012, by reviewing the attached press release (Exhibit 99.1), as the 8-K text does not contain these numbers.
- Confirm the specific vesting schedule and grant date valuation for Dr. Bahrami's restricted stock units ($25,644 value based on August 23, 2012 closing price).
- Monitor the company's progress toward the Fiscal 2013 revenue ($689 million) and non-GAAP EPS ($1.54) targets to assess potential executive bonus liabilities.
- Note the increase in non-employee director annual retainers from $25,000 to $30,000 and the new $80,000 annual equity grant value.